Aethlon Medical Explores the Hemopurifier's Potential Against H5N1
Aethlon Medical, Inc. (Nasdaq: AEMD) is focused on advancing medical technologies that aim to treat severe illnesses, particularly those caused by infectious diseases like the avian influenza H5N1, commonly known as Bird Flu. Recent developments have prompted the company to share insights about its investigational device, the Hemopurifier, and its capabilities in combating such threats.
The Rising Concern of H5N1 Influenza
The emergence of H5N1 in livestock and reports of human infections have raised serious health concerns among authorities. The isolation of H5N1 in dairy cows and reported cases in humans across various regions highlight the need for effective interventions. Aethlon has received numerous inquiries about the Hemopurifier's ability to deal with these situations.
How the Hemopurifier Works
The Hemopurifier is a clinical stage medical device designed to filter out enveloped viruses and other harmful particles from the bloodstream. Utilizing advanced technologies involving plasma separation, size exclusion, and affinity binding, the device targets viruses that possess sugar molecules like mannose on their surface. This is crucial for the Hemopurifier's functionality, especially with viruses like H5N1.
Successful In Vitro Studies
Aethlon Medical has previously partnered with Battelle labs to investigate the effectiveness of the Hemopurifier on H5N1 via in vitro testing. In these studies, the device was able to successfully remove 99% of the H5N1 virus from circulating samples after six hours of treatment, demonstrating significant potential for future application.
The Device's Clinical Applications
While the Hemopurifier has not yet been used on patients suffering from H5N1, it has shown promising results in treating other life-threatening infections. To date, the device has been utilized in 38 patients across 164 treatment sessions targeting serious conditions such as hepatitis C, HIV, COVID-19, and even Ebola. This diverse application underscores its potential effectiveness in managing severe viral infections.
FDA Designation and Future Monitoring
The Hemopurifier is recognized by the FDA as a “breakthrough device” aimed at addressing critical viral infections for which no adequate treatment exists. Given the current state of emergency declared in some regions related to H5N1, Aethlon plans to closely monitor developments in the landscape and engage with healthcare providers to prepare for potential future interventions.
Aethlon Medical: Leaders in Innovative Medical Solutions
Aethlon Medical is dedicated to revolutionizing treatment options for severe diseases through innovative technologies. The Hemopurifier exemplifies their commitment to addressing life-threatening conditions by efficiently capturing harmful viruses. Extensive research and successful clinical outcomes have propelled Aethlon’s standing as a pioneer in therapeutic solutions. By harnessing proprietary technology, the company continues to explore new frontiers in healthcare.
Frequently Asked Questions
What is the Hemopurifier device?
The Hemopurifier is an investigational medical device designed to filter and remove enveloped viruses from the bloodstream, thus aiming to treat serious viral infections.
How effective is the Hemopurifier against H5N1?
In laboratory tests, the Hemopurifier has been shown to remove 99% of H5N1 virus, indicating a strong potential for treating this infection in a clinical setting.
Has the Hemopurifier been used in clinical settings?
Yes, the Hemopurifier has been used in various clinical sessions targeting diseases like hepatitis C, HIV, and others, demonstrating its versatile application.
What regulatory status does the Hemopurifier have?
The Hemopurifier has received “breakthrough device” designation from the FDA, allowing for expedited development and review processes for critical medical devices.
What future developments should we expect from Aethlon Medical?
Aethlon Medical plans to monitor the situation regarding H5N1 closely and adapt its strategy as needed, engaging with healthcare providers to offer potential treatments for serious infections.
